[HTML][HTML] Immunogenicity of SARS-CoV-2 vaccines in patients with cancer
H Kakkassery, E Carpenter, PEM Patten… - Trends in Molecular …, 2022 - cell.com
Transmission of the SARS-CoV-2 virus and its corresponding disease (COVID-19) has been
shown to impose a higher burden on cancer patients than on the general population …
shown to impose a higher burden on cancer patients than on the general population …
Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial
A Thakkar, K Pradhan, B Duva, JM Carreno, S Sahu… - Elife, 2023 - elifesciences.org
Background: Cancer patients show increased morbidity with COVID-19 and need effective
immunization strategies. Many healthcare regulatory agencies recommend administering …
immunization strategies. Many healthcare regulatory agencies recommend administering …
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an …
N Uaprasert, P Pitakkitnukun… - Blood Cancer …, 2022 - nature.com
Patients with hematologic malignancies (HM) have demonstrated impaired immune
responses following SARS-CoV-2 vaccination. Factors associated with poor immunogenicity …
responses following SARS-CoV-2 vaccination. Factors associated with poor immunogenicity …
Efficacy of COVID-19 booster vaccines in patients with hematologic Malignancies: experiences in a real-world scenario
C Krekeler, L Reitnauer, U Bacher, C Khandanpour… - Cancers, 2022 - mdpi.com
Simple Summary The current study provides data on the efficacy of COVID-19 prime-boost
vaccines in 200 patients with hematologic and predominantly lymphoid malignancies as …
vaccines in 200 patients with hematologic and predominantly lymphoid malignancies as …
The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey
Since the beginning of the COVID-19 pandemic, there has been an overall improvement in
patient mortality. However, haematological malignancy patients continue to experience …
patient mortality. However, haematological malignancy patients continue to experience …
[HTML][HTML] Impact of Immunosuppressants and Vaccination on COVID-19 Outcomes in Autoimmune Patients and Solid Organ Transplant Recipients: A Nationwide …
M Sung, YS Kim, C Cho, Y Son, DW Kim, SH Lee - Vaccines, 2024 - mdpi.com
Purpose: This study investigates the impact of varying degrees of immunosuppression on
the clinical outcomes of immunocompromised individuals, particularly those with …
the clinical outcomes of immunocompromised individuals, particularly those with …
Severe acute respiratory syndrome coronavirus 2 infection in patients with hematological malignancies in the Omicron era: Respiratory failure, need for mechanical …
E Franceschini, V Menozzi, V Todisco, M Pellegrino… - …, 2024 - Wiley Online Library
Background: Patients with hematological malignancies (HM) have a high risk of severe
coronavirus disease 2019 (COVID‐19), also in the Omicron period. Material and methods …
coronavirus disease 2019 (COVID‐19), also in the Omicron period. Material and methods …
Efficacy and longevity of immune response to 3rd COVID-19 vaccine and effectiveness of a 4th dose in severely immunocompromised patients with cancer
A Thakkar, K Pradhan, B Duva, JM Carreño, S Sahu… - medRxiv, 2022 - medrxiv.org
Cancer patients show increased morbidity with COVID-19 and need effective immunization
strategies. We demonstrate that a 3rd dose of COVID-19 vaccine leads to seroconversion in …
strategies. We demonstrate that a 3rd dose of COVID-19 vaccine leads to seroconversion in …